Investors & Media

Overview

Webcast ImageWebcast
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology (Replay)
09/29/16 at 2:00 p.m. ET
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
Thursday, September 29, 2016 2:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies. The company’s objective is to develop and bring to market the most advanced products based on the transformative potential of gene therapy to provide patients hope for a better life in the face of limited or no long-term safe and effective treatment options. Headquartered in Cambridge, Massachusetts, bluebird bio has operations in the U.S. and Europe.

stock quote

NASDAQ: BLUE (common stock)

Refresh Quote
ExchangePriceChange (%)Volume
NASDAQ GS (US Dollar)
$67.78
 Stock is Up 1.37 (2.06%)
1,149,652
Data provided by Nasdaq. Minimum 15 minutes delayed.

Investor Contact

Manisha Pai

Sr. Director, Investor Relations

(617) 245-2107

investor@bluebirdbio.com


Media Contacts

Elizabeth Pingpank

Associate Director, Corporate Communications

(617) 914-8736

EPingpank@bluebirdbio.com


Dan Budwick

Senior Vice President, Media Relations

Pure Communications Inc.

(973) 271-6085

dan@purecommunicationsinc.com